Edesa Biotech (EDSA) Cash from Investing Activities (2013 - 2022)
Edesa Biotech (EDSA) posted Cash from Investing Activities of $41.0 for Q3 2022, up 103.02% sequentially from -$1358.0 in Q2 2022, and down 97.2% YoY from $1464.0 in Q3 2021.
Edesa Biotech (EDSA) Cash from Investing Activities (2013 - 2022) Analysis & Trends
Edesa Biotech has reported Cash from Investing Activities for 10 years, with the latest figure at $41.0 in Q3 2022.
- Quarterly Cash from Investing Activities fell 97.2% year-over-year to $41.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $41.0 (up 100.97% YoY) and the FY2022 annual result came in at -$5656.0, up 7.97% from the prior year.
- Cash from Investing Activities advanced to $41.0 in Q3 2022 per EDSA's latest filing, from -$1358.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $6.4 million in Q2 2019 and troughed at -$635887.0 in Q3 2018.
- A 5-year average of $408291.8 and a median of -$1199.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2019 and 2021: Cash from Investing Activities surged 93348.03% in 2019, then tumbled 176.65% in 2021.
- Over 5 years, Cash from Investing Activities stood at -$635887.0 in 2018, then climbed by 24.94% to -$477293.0 in 2019, then surged by 99.76% to -$1135.0 in 2020, then slumped by 176.65% to -$3140.0 in 2021, then surged by 101.31% to $41.0 in 2022.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $41.0, -$1358.0, and -$1199.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 41.00 |
| Sep 30, 2022 | 41.00 |
| Jun 30, 2022 | -1,358.00 |
| Jun 30, 2022 | -1,358.00 |
| Mar 31, 2022 | -1,199.00 |
| Mar 31, 2022 | -1,199.00 |
| Dec 31, 2021 | -3,140.00 |
| Dec 31, 2021 | -3,140.00 |
| Sep 30, 2021 | 1,464.00 |
| Sep 30, 2021 | 1,464.00 |
| Jun 30, 2021 | -3,512.00 |
| Jun 30, 2021 | -3,512.00 |
| Mar 31, 2021 | -2,963.00 |
| Mar 31, 2021 | -2,963.00 |
| Dec 31, 2020 | -1,135.00 |
| Dec 31, 2020 | -1,135.00 |
| Sep 30, 2020 | 3,541.00 |
| Sep 30, 2020 | 3,541.00 |
| Mar 31, 2020 | 519,652.00 |
| Mar 31, 2020 | 519,652.00 |